Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 4Phase 1/2 2Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2009Carcinoma, Non-Small-Cell Lung 1222Breast Neoplasms 1214Leukemia, Myeloid, Acute 965Neoplasm Metastasis 900Melanoma 777Colorectal Neoplasms 749Lymphoma 725Multiple Myeloma 723Ovarian Neoplasms 673Pancreatic Neoplasms 664Prostatic Neoplasms 657Lymphoma, Non-Hodgkin 657Recurrence 636Precursor Cell Lymphoblastic Leukemia-Lymphoma 583Lung Neoplasms 559Leukemia, Lymphocytic, Chronic, B-Cell 555Glioblastoma 527Leukemia 485Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 418Brain Neoplasms 413Squamous Cell Carcinoma of Head and Neck 388Stomach Neoplasms 386Carcinoma, Renal Cell 384Myelodysplastic Syndromes 381Carcinoma, Hepatocellular 367Advanced Solid Tumors 356Lymphoma, Mantle-Cell 345Glioma 342

Interventions

pembrolizumab 1Radiation Dose Hypofractionation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Interventional × Urothelial Cancer × Clear all
NCT02880345 2019-04-23

RADVAXâ„¢: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy

Abramson Cancer Center at Penn Medicine

Phase 1 Withdrawn
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡